论文部分内容阅读
目的观察长春瑞滨联合顺铂治疗中晚期非小细胞肺癌的临床疗效及毒副反应。方法 68例非小细胞肺癌患者随机分为观察组和对照组,各34例。观察组患者应用长春瑞滨、顺铂联合治疗,对照组应用环磷酰胺、阿霉素、顺铂联合治疗。治疗2个周期后,观察两组患者的临床疗效及毒副反应。结果 68例患者均完成2个周期治疗,观察组患者总有效率为47.06%(16/34),对照组患者总有效率为26.47%(9/34),两组患者总有效率比较差异有统计学意义(P<0.05);两组患者毒副反应轻微可耐受,经对症处置后未影响下一周期治疗。结论长春瑞滨、顺铂联合化疗方案治疗中晚期非小细胞肺癌具有临床疗效较好,毒副反应轻等优点,值得临床进一步研究应用。
Objective To observe the clinical efficacy and side effects of vinorelbine plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods Sixty-eight patients with non-small cell lung cancer were randomly divided into observation group and control group, with 34 cases in each group. The observation group patients with vinorelbine, cisplatin combination therapy, the control group with cyclophosphamide, doxorubicin, cisplatin combination therapy. After two cycles of treatment, the clinical efficacy and side effects of the two groups were observed. Results 68 patients completed 2 cycles of treatment, the total effective rate was 47.06% (16/34) in the observation group and 26.47% (9/34) in the control group. There was significant difference between the two groups in the total effective rate Statistical significance (P <0.05); two groups of patients with mild side effects were tolerable, after symptomatic treatment did not affect the next cycle of treatment. Conclusion Vinorelbine combined with cisplatin in the treatment of advanced non-small cell lung cancer with good clinical efficacy, mild toxicity, merits the clinical further study and application.